Human IgG1κ anti-CD38 monoclonal antibody (brand name Darzalex) given intravenously; binds CD38 on leukemic cells to induce ADCC, CDC, ADCP, and apoptosis, and inhibits CD38 ectoenzyme (NADase) activity to reduce adenosine-mediated immunosuppression.
Human IgG1-kappa anti-CD38 monoclonal antibody that binds CD38 on tumor cells to induce antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis; also depletes CD38+ immunosuppressive cells and inhibits CD38 ectoenzyme (NADase) activity to reduce adenosine-mediated immunosuppression.
YES
DIRECT
Daratumumab binds CD38 on target cells and triggers Fc-mediated ADCC, complement-dependent cytotoxicity, and antibody-dependent phagocytosis; crosslinking can also induce apoptosis of CD38+ cells.
CD47-blocking SIRPα–IgG4 Fc fusion protein (PF-07901801; TTI-622) that disrupts the CD47 'don't eat me' signal to promote macrophage phagocytosis.
Soluble SIRPα–IgG4 Fc fusion that binds CD47 on tumor cells and blocks the CD47–SIRPα innate immune checkpoint, removing the 'don’t‑eat‑me' signal and activating macrophages to promote phagocytosis and antitumor clearance.
YES
INDIRECT
Blocks the CD47–SIRPα inhibitory checkpoint on tumor cells, enabling macrophage activation and phagocytosis (ADCP) to clear CD47-expressing cells.
Fc-enhanced anti-CD19 humanized IgG monoclonal antibody (Monjuvi) that induces ADCC/ADCP and apoptosis of B cells.
Fc-enhanced humanized anti-CD19 IgG monoclonal antibody that binds CD19 on B cells and promotes Fcγ receptor–mediated ADCC and ADCP, leading to apoptosis and depletion of malignant B cells.
YES
DIRECT
Binds CD19 on B cells and recruits FcγR-bearing effector cells to induce ADCC and ADCP, leading to apoptosis and depletion of CD19+ cells.
Fc-enhanced anti-CD19 humanized IgG monoclonal antibody (Monjuvi) that induces ADCC/ADCP and apoptosis of B cells.
Fc-enhanced humanized anti-CD19 IgG monoclonal antibody that binds CD19 on B cells and promotes Fcγ receptor–mediated ADCC and ADCP, leading to apoptosis and depletion of malignant B cells.
NO
INDIRECT
Tafasitamab binds CD19 on B cells and its Fc engages CD16A on NK cells/monocytes to trigger ADCC/ADCP that kills CD19+ cells; CD16A-expressing effector cells are not targeted or killed by the drug.
Actinium-225–conjugated FPI-2053 targeted alpha therapy that binds EGFR/cMET and delivers high-LET alpha radiation causing DNA double-strand breaks and tumor cell kill.
Bispecific anti-EGFR/c-MET humanized antibody (FPI-2053) chelated to DOTA and radiolabeled with actinium-225; targets EGFR/c-MET on tumor cells and delivers high-LET alpha radiation that causes DNA double-strand breaks and tumor cell death, with potential secondary anti-tumor immune activation from antigen release.
YES
DIRECT
The bispecific antibody binds EGFR on tumor cells and delivers actinium‑225 alpha radiation, causing high‑LET DNA double‑strand breaks and lethal damage (apoptosis/necrosis) without requiring immune-cell engagement.